The rationale for evaluating the clinical activity of MLN8237 in T-cell lymphomas is further supported by recent preclinical studies showing that both AAK and Aurora B kinase are expressed in T-cell lymphoma cell lines [33] and in patient samples from the SWOG S0350 study [34], and that MLN8237 induces endo-reduplication and apoptosis in PTCL cell lines [33]. This evidence concerns the gene AURKB and T-cell non-Hodgkin lymphoma.